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Mohs micrographic surgery remains the gold
standard for the treatment of cutaneous squamous
cell carcinomas (SCCs) of the head and neck.
However, for recurrent or aggressive SCCs, it can
be challenging at times to ensure complete margin
control on hematoxylin and eosin (H&E) frozen
sections alone. The authors present a case of
multiple recurrent SCC that was ultimately found to
have occult foci of tumor identifiable only by anti-
cytokeratin immunohistochemistry (IHC). Although
a large volume of literature addresses the topic of
IHC for melanocytic neoplasms treated by traditional
Mohs and ‘‘slow Mohs,’’ there is a relative paucity of
commentary on its use in SCCs.1 This unusual case
highlights the importance of anticytokeratin IHC for
SCCs, especially in tumors that are recurrent or have
aggressive or atypical cytomorphology.Fig 1. Original biopsy shows SCC infiltrating into the
papillary dermis. (H&E stain; original magnification:310.)CASE REPORT
A 63-year-old woman with a medical history
significant for 2 basal cell carcinomas, follicular
lymphoma, and breast cancer presented for evalu-
ation of an 8-mm infiltrative erythematous papule
on the left lateral cheek near the angle of the
mandible. There was no nerve pain, pruritus, or
other clinical indicator of perineural invasion. A
biopsy of the lesion found a well-differentiated
invasive SCC (Fig 1), which was excised via the
Mohs technique and repaired with a small advance-
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from the prior Mohs procedure without regional
lymphadenopathy. Biopsy of the lesion found
well-differentiated and invasive SCC in a background
of scar and repair changes. The pathologists noted in
their report that the specimen had architectural andJAAD Case Reports 2016;2:346-9.
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Fig 2. Permanent sections of the Mohs layer did not show
SCC. (H&E stain; original magnification: 34.)
Fig 3. Permanent sections of the Mohs layer did not show
SCC. (H&E stain; original magnification: 320.)
Fig 4. IHC using AE1/AE3 shows irregular infiltrating
strands of SCC and scattered single atypical cells. (AE1/
AE3 stain; original magnification: 320.)
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tumor, specifically noting marked nuclear pleomor-
phism and an infiltrative growth pattern. The tumor
was re-excised using the Mohs technique. Given the
aggressive histopathologic appearance, referral was
also made to the radiation oncology department.
Although recommended at that time to undergo a
dedicated planning computed tomography scan
in anticipation of adjuvant radiation, the patient
declined both the computed tomography scan and
the adjuvant radiation.
Two years later, the patient was again found to
have a lesion suspicious for recurrence—this time a
7-mm firm, tender, erythematous papule within the
scar. There was no regional lymphadenopathy.
Biopsy and subsequent histopathologic examination
foundwell-differentiated and invasive SCC at the site,
with aggressive features as before, including marked
nuclear pleomorphism and a highly infiltrative
growth pattern. For this second recurrence, the
patient was again treated with Mohs micrographic
surgery, which was thought to be clear after 3 stages
and closed with an advancement flap.
Eight months later, the patient noted a small area of
ulceration within the inferior portion of the scar.Rebiopsy found well-differentiated SCC again. At
that time, a dedicated computed tomography scan of
the face and neck/larynx with contrast found no
radiographic evidence of tumor or lymphadenopathy.
The patient subsequently underwent her fourth Mohs
procedure, which was thought to be clear after 2
stages. However, this time, the final stages were sent
for formalin-embeddedpermanent sections tobe read
by a dermatopathologist prior to definitive closure
(Figs 2 and 3). This action was done because of the
multiple recurrences of the tumor and an inflamma-
tory infiltrate noted on frozen section potentially
obscuring occult foci of tumor, a feature that had not
been noted during any of the patient’s previous Mohs
procedures. On histopathologic examination, no re-
sidual SCC was identified on H&E, so the defect was
then closed as planned. Given the unusual circum-
stances of the case and development of additional
nonmelanoma skin cancers at other sites over the
same period, the patient was started on acitretin. She
was also evaluated by radiation oncology for a second
time, but the patient remained reluctant to undergo
any radiation therapy.
One year later, the patient had a suspicious lesion
at the same site, and rebiopsy found well-
differentiated invasive SCC again. At this time, given
the unusual nature of the case, anticytokeratin
staining (AE1/AE3) was performed on the block
sent for frozen section from the most recent Mohs
procedure 1 year prior. Despite no residual SCC
identified on H&E by an experienced dermatopa-
thologist, AE1/AE3 staining found a minute focus of
infiltrating cells in the papillary dermis suspicious for
residual SCC (Fig 4). Given the apparent impossi-
bility of fully characterizing the tumor on H&E and its
multiple recurrences, Mohs was no longer felt to be
an appropriate treatment modality. The patient then
was sent to the otolaryngology department for a
wide local excision with parotidectomy and
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findings showed residual SCC invading to a
maximum depth of 4 mm and a maximum width of
1.5 cm. There was no invasion of the subcutaneous
fat or into the parotid capsule. Eight lymph nodes,
including 6 from the neck and 2 intraparotid nodes,
were negative for malignancy. She was again
referred to the radiation oncology department, who
discussed with her the pros and cons of adjuvant
radiation therapy versus close observation. The
patient elected observation, and she has had no
evidence of recurrence at the site after an additional
26 months of follow-up.DISCUSSION
Mohs micrographic surgery as it is customarily
practiced relies on accurate identification of tumor
extension on frozen sections stained with H&E.
However, as illustrated by this case, there are certain
circumstances in which tumor characteristics
preclude obtaining complete margin control on
H&E alone. One study using rapid staining for AE1
found hidden foci of SCC in 8 of 20 (40%) of the
extensive, aggressive, or recurrent SCCs analyzed.2
In our patient’s case, there is also a known
association between concomitant non-Hodgkin’s
lymphomas, such as follicular lymphoma, and a
dramatically increased risk for SCC.3 It is possible
that the patient’s underlying immune dysregulation
secondary to her lymphoid neoplasm may have also
contributed to the aggressive behavior of the tumor
and subsequent difficulty in histologic detection.
Several stains are available that are useful for
highlighting squamous cell carcinoma, including
AE1/AE3 (a broad-spectrum anticytokeratin stain),
anticytokeratin 14, MNF116 (a collection of mono-
clonal antibodies to cytokeratins 5, 6, 8, 17, and 19),
and p63.4 Despite the utility of these stains in certain
clinical situations, according to a 2001 survey only 13
of 108 (12%) of American College of Mohs Surgery
laboratories were using real-time IHC, of which
only some reported using anticytokeratin stains.5
However, recent advances, including a new
validated 19-minute staining protocol for AE1/AE3,
the most commonly used anticytokeratin stain, have
mitigated some of the concerns related to increased
processing times and higher costs.6 Of note, it is
permissible to send Mohs stages for paraffin-
embedded permanent sections in specific circum-
stances. According to the American Academy of
Dermatology position statement on the topic, these
include scenarios in which a tumor has aggressive
histologic features or there is difficulty in ensuring
accurate margin control.7Adjuvant radiation therapy (ART) after surgical
excisions of SCCs is a controversial topic. Although
there are no clear consensus guidelines on when
to use postsurgical ART, both the National
Comprehensive Cancer Network and the American
College of Radiology recommend ART in the setting
of significant perineural invasion, which was not
present in our case.8,9 However, ART is also
generally considered in the setting of lymph node
involvement, invasion of the cranium, or, as in our
case, when there are several high-risk features or
multiple recurrences.10 Importantly, in high-risk
SCC, analysis of the central debulking from the
Mohs procedure can be particularly useful before
referral for adjuvant radiation, as it can offer further
information regarding depth of invasion, perineural
invasion, and other high-risk features potentially not
identified in the original biopsy.
This case shows 2 major teaching points. First, it is
extremely important to remain cognizant of the
high-risk features of cutaneous SCCs, which, in this
case, include concurrent hematologic malignancy,
aggressive histologic features, and recurrent status. It
is especially vital in these cases to ensure accurate
margin control, strategies for which could include
review of the original biopsy by the surgeon, careful
analysis of the debulking specimen to familiarize
oneself with the particular histopathology of a given
tumor, or the use of immunohistochemistry. Second,
this report illustrates the particular benefits of
anticytokeratin IHC for patients with recurrent and
aggressive SCCs and in those with underlying immune
dysregulation, either with rapid staining protocols if
available or, if not, on permanent sections using
the slow Mohs technique. In cases such as this one,
IHC can serve as a valuable tool to minimize excess
morbidity in the management of squamous cell
carcinoma.
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